Researchers identify distinct gut microbiome metabolites in women with endometriosis, offering potential for non-invasive diagnosis and new therapies.
Anthos’ detailed mid-stage data back its anticoagulant, but can the drug succeed where Bayer’s failed?
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
January 24, 2025